Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study

被引：0

作者：

Ewenstein, B. M. ^{[1
]}

Reininger, A. J. ^{[2
]}

机构：

[1] Baxter Healthcare Corp, Westlake Village, CA 91362 USA

[2] Baxter Healthcare SA, European Headquarters, Zurich, Switzerland

来源：

HAEMOPHILIA | 2011年 / 17卷 / 05期

关键词：

PREVIOUSLY UNTREATED PATIENTS; HEMOPHILIA-A; REPLACEMENT;

D O I：

10.1111/j.1365-2516.2011.02605.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：E847 / E848

页数：2

相关论文

共 9 条

[1] *EMA, 2006, REP EXP M FACT 8 PRO
[2] *EMEA, EMEA PUBL STAT REV R
[3] Risk of inhibitors in haemophilia and the type of factor replacement
Goudemand, Jenny
Laurian, Yves
Calvez, Thierry
[J]. CURRENT OPINION IN HEMATOLOGY, 2006, 13 (05) : 316 - 322
[4] The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment
Gouw, Samantha C.
van den Berg, H. Maryke
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2009, 35 (08) : 723 - 734
[5] KLUKOWSKA A, 2010, HAEMOPHILIA, V17, P1
[6] Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: A final report on a hallmark clinical
Lusher, J
Abildgaard, C
Arkin, S
Mannucci, PM
Zimmermann, R
Schwartz, L
Hurst, D
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (04) : 574 - 583
[7] Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy
Peerlinck, K.
Hermans, C.
[J]. HAEMOPHILIA, 2006, 12 (06) : 579 - 590
[8] White GC, 1999, THROMB HAEMOSTASIS, V81, P462
[9] Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A
Yoshioka, A
Fukutake, K
Takamatsu, J
Shirahata, A
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 78 (05) : 467 - 474